Myrcludex B
Myrcludex B is an experimental drug for the treatment of hepatitis B and D.[1] The first Phase IIa clinical trials with 40 patients concluded in 2014, finding that the drug was well tolerated and, as far as can be said with the limited data, effective against hepatitis B.[2]
Mechanism of action[edit | edit source]
The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1[3][4] that can also dock to NTCP, blocking the virus's entry mechanism.[1]
The drug is also effective against hepatitis D because the hepatitis D virus is only infective in the presence of a hepatitis B virus infection.[1]
References[edit | edit source]
 | This antiinfective drug article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
